Anti-B-Cell Therapies in Autoimmune Neurological Diseases: Rationale and Efficacy Trials

[1]  G. Comi,et al.  Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients , 2016, Multiple sclerosis.

[2]  E. C. Teo,et al.  A review of monoclonal antibody therapies in lymphoma. , 2016, Critical reviews in oncology/hematology.

[3]  M. Fujimoto,et al.  Regulatory B cells in human inflammatory and autoimmune diseases: from mouse models to clinical research. , 2015, International immunology.

[4]  E. Waubant,et al.  Prolonged Remission in Neuromyelitis Optica Following Cessation of Rituximab Treatment , 2015, Journal of child neurology.

[5]  J. Joo,et al.  Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica: Influence of FCGR3A Polymorphisms on the Therapeutic Response to Rituximab. , 2015, JAMA neurology.

[6]  Manuel A. Friese,et al.  Immunopathology of multiple sclerosis , 2015, Nature Reviews Immunology.

[7]  Chung-Jen Chen,et al.  Inflammatory Muscle Diseases. , 2015, The New England journal of medicine.

[8]  P. Smolewski,et al.  Emerging immunological drugs for chronic lymphocytic leukemia , 2015, Expert opinion on emerging drugs.

[9]  M. Dalakas,et al.  Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis , 2015, Neurology: Neuroimmunology & Neuroinflammation.

[10]  M. Menon,et al.  The expanding family of regulatory B cells , 2015, International immunology.

[11]  I. Sanz,et al.  Expansion of Activated Peripheral Blood Memory B Cells in Rheumatoid Arthritis, Impact of B Cell Depletion Therapy, and Biomarkers of Response , 2015, PloS one.

[12]  P. Zdziarski.  A Case of Stiff Person Syndrome: Immunomodulatory Effect of Benzodiazepines , 2015, Medicine.

[13]  T. Cai,et al.  The immune balance between memory and regulatory B cells in NMO and the changes of the balance after methylprednisolone or rituximab therapy , 2015, Journal of Neuroimmunology.

[14]  Jiusheng Deng,et al.  Blood B Cell and Regulatory Subset Content in Multiple Sclerosis Patients , 2015, Journal of multiple sclerosis.

[15]  E. Rosser,et al.  Regulatory B cells: origin, phenotype, and function. , 2015, Immunity.

[16]  M. Lucchetta,et al.  Polyneuropathy with anti-sulfatide and anti-MAG antibodies: Clinical, neurophysiological, pathological features and response to treatment , 2015, Journal of Neuroimmunology.

[17]  C. Klein,et al.  Obinutuzumab (GA101) for the Treatment of Chronic Lymphocytic Leukemia and Other B-Cell Non-Hodgkin's Lymphomas: A Glycoengineered Type II CD20 Antibody , 2015, Oncology Research and Treatment.

[18]  K. Fujihara,et al.  MOG cell-based assay detects non-MS patients with inflammatory neurologic disease , 2015, Neurology: Neuroimmunology & Neuroinflammation.

[19]  T. Kurosaki,et al.  Memory B cells , 2015, Nature Reviews Immunology.

[20]  M. Dalakas,et al.  Autoimmune antigenic targets at the node of Ranvier in demyelinating disorders , 2015, Nature Reviews Neurology.

[21]  J. Gilthorpe,et al.  Rapid depletion of B lymphocytes by ultra-low-dose rituximab delivered intrathecally , 2015, Neurology: Neuroimmunology & Neuroinflammation.

[22]  Philip D. Hodgkin,et al.  The generation of antibody-secreting plasma cells , 2015, Nature Reviews Immunology.

[23]  J. Herbert,et al.  Disease exacerbation after rituximab induction in neuromyelitis optica , 2015, Neurology: Neuroimmunology & Neuroinflammation.

[24]  S. Sciascia,et al.  Biologicals for the treatment of systemic lupus erythematosus: current status and emerging therapies , 2015, Expert review of clinical immunology.

[25]  M. Dalakas.  Inflammatory Muscle Diseases. , 2015, The New England journal of medicine.

[26]  V. Damato,et al.  Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis , 2015, Journal of Neurology.

[27]  P. Valentino,et al.  CD19 mRNA quantification improves rituximab treatment-to-target approach: A proof of concept study , 2014, Journal of Neuroimmunology.

[28]  D. Laplaud,et al.  Unaltered regulatory B-cell frequency and function in patients with multiple sclerosis. , 2014, Clinical immunology.

[29]  H. Hartung,et al.  IVIG regulates BAFF expression in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) , 2014, Journal of Neuroimmunology.

[30]  S. Baranzini,et al.  Rituximab Efficiently Depletes Increased CD20-Expressing T Cells in Multiple Sclerosis Patients , 2014, The Journal of Immunology.

[31]  E. Waubant,et al.  Rituximab use in pediatric central demyelinating disease. , 2014, Pediatric neurology.

[32]  R. Gold,et al.  Trial and error in clinical studies: lessons from ATAMS , 2014, The Lancet Neurology.

[33]  Amit Bar-Or,et al.  IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases , 2014, Nature.

[34]  Anne-Kathrin Kienzler,et al.  B cell Biology: An Overview , 2014, Current Allergy and Asthma Reports.

[35]  Jacqueline A Palace,et al.  Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. , 2014, JAMA neurology.

[36]  Andriy I. Bandos,et al.  Predictors of Clinical Improvement in Rituximab‐Treated Refractory Adult and Juvenile Dermatomyositis and Adult Polymyositis , 2014, Arthritis & rheumatology.

[37]  M. Filippi,et al.  Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis , 2014, Neurology.

[38]  P. Tak,et al.  Safety with Ocrelizumab in Rheumatoid Arthritis: Results from the Ocrelizumab Phase III Program , 2014, PloS one.

[39]  Raymond D. Schellevis,et al.  Fcγ receptor IIIA genotype is associated with rituximab response in antimyelin-associated glycoprotein neuropathy , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[40]  Y. Messinger,et al.  Ofatumumab for refractory opsoclonus‐myoclonus syndrome following treatment of neuroblastoma , 2013, Pediatric blood & cancer.

[41]  A. Ahmed,et al.  Preliminary analysis of mortality associated with rituximab use in autoimmune diseases , 2013, Autoimmunity.

[42]  A. Bar-Or,et al.  Dynamics of B-Cell Populations in CSF and Blood in Patients Treated with a Combination of Rituximab and Mitoxantrone , 2013, ISRN neurology.

[43]  R. Maciuca,et al.  Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. , 2013, Arthritis and rheumatism.

[44]  Su-Hyun Kim,et al.  A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. , 2013, JAMA neurology.

[45]  J. Goldstein,et al.  Long-term benefit of rituximab in MuSK autoantibody myasthenia gravis patients , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[46]  A. Lutterotti,et al.  Clinical and immunological follow-up of B-cell depleting therapy in CNS demyelinating diseases , 2013, Journal of the Neurological Sciences.

[47]  Bodo Grimbacher,et al.  B-cell biology and development. , 2013, The Journal of allergy and clinical immunology.

[48]  C. Akdis,et al.  IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses. , 2013, The Journal of allergy and clinical immunology.

[49]  Gui-xian Zhao,et al.  Impaired regulatory function and enhanced intrathecal activation of B cells in neuromyelitis optica: distinct from multiple sclerosis , 2013, Multiple sclerosis.

[50]  C. Cunningham-Rundles,et al.  Immune deficiencies , infection , and systemic immune disorders TACI mutations and impaired B-cell function in subjects with CVID and healthy heterozygotes , 2013 .

[51]  H. Rockette,et al.  Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. , 2013, Arthritis and rheumatism.

[52]  V. Mok,et al.  Rituximab reduces attacks in Chinese patients with neuromyelitis optica spectrum disorders , 2013, Journal of the Neurological Sciences.

[53]  H. Gadner,et al.  Isolated cutaneous Langerhans cell histiocytosis in a premature baby: What is the optimal approach? , 2013, Pediatric blood & cancer.

[54]  L. Piccio,et al.  Rituximab combination therapy in relapsing multiple sclerosis , 2012, Therapeutic advances in neurological disorders.

[55]  V. Lougaris,et al.  A novel compound heterozygous TACI mutation in an autosomal recessive common variable immunodeficiency (CVID) family. , 2012, Human immunology.

[56]  M. Pranzatelli,et al.  Ofatumumab for a rituximab‐allergic child with chronic‐relapsing paraneoplastic opsoclonus–myoclonus , 2012, Pediatric blood & cancer.

[57]  J. Lünemann,et al.  Rituximab induces sustained reduction of pathogenic B cells in patients with peripheral nervous system autoimmunity. , 2012, The Journal of clinical investigation.

[58]  Yoshiya Tanaka,et al.  Safety and Efficacy of Various Dosages of Ocrelizumab in Japanese Patients with Rheumatoid Arthritis with an Inadequate Response to Methotrexate Therapy: A Placebo-controlled Double-blind Parallel-group Study , 2012, The Journal of Rheumatology.

[59]  A. Nielsen,et al.  Maximally tolerated versus minimally effective dose: the case of rituximab in multiple sclerosis , 2012, Multiple sclerosis.

[60]  J. Kremer,et al.  Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: results of a forty-eight–week randomized, double-blind, placebo-controlled, parallel-group phase III trial. , 2012, Arthritis and rheumatism.

[61]  B. Combe,et al.  Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial. , 2012, Arthritis and rheumatism.

[62]  C. Zerbini,et al.  Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial , 2012, Annals of the rheumatic diseases.

[63]  王凯,et al.  Cerebrospinal fluid BAFF and APRIL levels in neuromyelitis optica and multiple sclerosis patients during relapse , 2012 .

[64]  H. Hartung,et al.  Guillain-Barré syndrome. , 2012, The New England journal of medicine.

[65]  F. Barkhof,et al.  Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial , 2011, The Lancet.

[66]  Su-Hyun Kim,et al.  Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. , 2011, Archives of neurology.

[67]  P. Menheere,et al.  Reduction in IL-10 producing B cells (Breg) in multiple sclerosis is accompanied by a reduced naïve/memory Breg ratio during a relapse but not in remission , 2011, Journal of Neuroimmunology.

[68]  B. Lam,et al.  Impact of rituximab on relapse rate and disability in neuromyelitis optica , 2011, Multiple sclerosis.

[69]  M. Dalakas.  Inflammatory myopathies: management of steroid resistance. , 2011, Current opinion in neurology.

[70]  M. Dalakas.  Advances in the diagnosis, pathogenesis and treatment of CIDP , 2011, Nature Reviews Neurology.

[71]  J. Goldstein,et al.  Response of patients with refractory myasthenia gravis to rituximab: a retrospective study , 2011, Therapeutic advances in neurological disorders.

[72]  Y. Itoyama,et al.  Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels , 2011, Journal of Clinical Neuroscience.

[73]  Y. Mori,et al.  Bcl6 protein expression shapes pre-germinal center B cell dynamics and follicular helper T cell heterogeneity. , 2011, Immunity.

[74]  M. Krumbholz,et al.  Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab , 2011, Neurology.

[75]  K. Kaida,et al.  Antibodies against ganglioside complexes in Guillain‐Barré syndrome and related disorders , 2011, Journal of neurochemistry.

[76]  K. Silver,et al.  Efficacy and Safety of Rituximab in Pediatric Neuromyelitis Optica , 2011, Journal of child neurology.

[77]  E. S. St. Clair,et al.  Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. , 2011, Blood.

[78]  A. Qureshi,et al.  Stiff person syndrome (SPS) complicated by respiratory failure: successful treatment with rituximab , 2011, Journal of Neurology.

[79]  M. Haroon,et al.  Rituximab as a first-line agent for the treatment of dermatomyositis , 2012, Rheumatology International.

[80]  N. Allam,et al.  Stiff-person syndrome treated with rituximab , 2010, BMJ Case Reports.

[81]  C. Wessig,et al.  Stiff person syndrome-associated autoantibodies to amphiphysin mediate reduced GABAergic inhibition. , 2010, Brain : a journal of neurology.

[82]  Nitin J. Karandikar,et al.  Memory B cells from a subset of treatment‐naïve relapsing‐remitting multiple sclerosis patients elicit CD4+ T‐cell proliferation and IFN‐γ production in response to myelin basic protein and myelin oligodendrocyte glycoprotein , 2010, European journal of immunology.

[83]  M. Shlomchik,et al.  B-Cell Depletion In Vitro and In Vivo with an Afucosylated Anti-CD19 Antibody , 2010, Journal of Pharmacology and Experimental Therapeutics.

[84]  T. Tedder,et al.  Regulatory B Cells (B10 Cells) and Regulatory T Cells Have Independent Roles in Controlling Experimental Autoimmune Encephalomyelitis Initiation and Late-Phase Immunopathogenesis , 2010, The Journal of Immunology.

[85]  R. Tehrani,et al.  Stiff-person syndrome: persistent elevation of glutamic acid decarboxylase antibodies despite successful treatment with rituximab. , 2010, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[86]  D. Jelinek,et al.  The Structure of the TNFRSF13C Promoter Enables Differential Expression of BAFF-R during B Cell Ontogeny and Terminal Differentiation , 2010, The Journal of Immunology.

[87]  H. Eibel,et al.  Long-Lived Plasma Cells and Memory B Cells Produce Pathogenic Anti-GAD65 Autoantibodies in Stiff Person Syndrome , 2010, PloS one.

[88]  S. Kikuchi,et al.  Decreased IL-10 production mediated by Toll-like receptor 9 in B cells in multiple sclerosis , 2010, Journal of Neuroimmunology.

[89]  H. Gil,et al.  Rituximab treatment of stiff-person syndrome in a patient with thymoma, diabetes mellitus and autoimmune thyroiditis , 2010, Journal of Clinical Neuroscience.

[90]  S. Kong,et al.  Interferon‐stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy , 2010, Annals of neurology.

[91]  H. Morita,et al.  Successful treatment with rituximab in a patient with stiff-person syndrome complicated by dysthyroid ophthalmopathy. , 2010, Internal medicine.

[92]  S. Cepok,et al.  Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease , 2009, Annals of neurology.

[93]  H. Sasaki,et al.  Memory and naïve B-cell subsets in patients with multiple sclerosis , 2009, Neuroscience Letters.

[94]  P. Calabresi,et al.  Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double‐blind placebo‐controlled multicenter trial , 2009, Annals of neurology.

[95]  A. Rolink,et al.  Tolerance checkpoints in B‐cell development: Johnny B good , 2009, European journal of immunology.

[96]  D. West,et al.  Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. , 2009, The Lancet. Oncology.

[97]  T. Montine,et al.  Depletion of B lymphocytes from cerebral perivascular spaces by rituximab. , 2009, Archives of neurology.

[98]  I. Sanz,et al.  Novel Human Transitional B Cell Populations Revealed by B Cell Depletion Therapy1 , 2009, The Journal of Immunology.

[99]  Haitao Wu,et al.  Identification of BLyS (B Lymphocyte Stimulator), a Non-Myelin-Associated Protein, as a Functional Ligand for Nogo-66 Receptor , 2009, The Journal of Neuroscience.

[100]  Hans Lassmann,et al.  The relation between inflammation and neurodegeneration in multiple sclerosis brains , 2009, Brain : a journal of neurology.

[101]  W. Oertel,et al.  Impaired inhibitory Fcγ receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy , 2009, Proceedings of the National Academy of Sciences.

[102]  J. Dambrosia,et al.  Placebo‐controlled trial of rituximab in IgM anti–myelin‐associated glycoprotein antibody demyelinating neuropathy , 2009, Annals of neurology.

[103]  E. Mayatepek,et al.  ‘Rituximab as a highly effective treatment in a female adolescent with severe multiple sclerosis’ , 2009, Developmental medicine and child neurology.

[104]  A. Rubbert-Roth,et al.  Rituximab levels in cerebrospinal fluid of patients with neurological autoimmune disorders , 2009, Multiple sclerosis.

[105]  J. Leavitt.  Treatment of Neuromyelitis Optica With Rituximab: Retrospective Analysis of 25 Patients , 2009 .

[106]  J. C. Callejas Rubio,et al.  Rituximab in the treatment of dermatomyositis and other inflammatory myopathies. A report of 4 cases and review of the literature. , 2009, Clinical and experimental rheumatology.

[107]  J. Kuemmerle-Deschner,et al.  Rituximab for the treatment of refractory pediatric autoimmune diseases: a case series , 2009, Cases journal.

[108]  R. Lewis,et al.  A potential role for B-cell activating factor in the pathogenesis of autoimmune myasthenia gravis. , 2008, Archives of neurology.

[109]  T. Takeuchi,et al.  Effect of interleukin-2 on synthesis of B cell activating factor belonging to the tumor necrosis factor family (BAFF) in human peripheral blood mononuclear cells. , 2008, Cytokine.

[110]  Dennis McGonagle,et al.  Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. , 2008, Arthritis and rheumatism.

[111]  M. Dalakas,et al.  B cells as therapeutic targets in autoimmune neurological disorders , 2008, Nature Clinical Practice Neurology.

[112]  R. De Palma,et al.  Rituximab in relapsing-remitting multiple sclerosis. , 2008, The New England journal of medicine.

[113]  M. Krumbholz,et al.  Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. , 2008, Brain : a journal of neurology.

[114]  T. Dörner,et al.  Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. , 2008, Arthritis and rheumatism.

[115]  D. Arnold,et al.  Rituximab in relapsing‐remitting multiple sclerosis: A 72‐week, open‐label, phase I trial , 2008, Annals of neurology.

[116]  D. Arnold,et al.  B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. , 2008, The New England journal of medicine.

[117]  X. Mariette,et al.  B‐cell Activating Factor of the Tumour Necrosis Factor Family Expression in Blood Monocytes and T Cells from Patients with Primary Sjögren’s Syndrome , 2008, Scandinavian journal of immunology.

[118]  Meit A. Bjorndahl,et al.  Articles on similar topics can be found in the following Blood collections , 2006 .

[119]  M. Dalakas.  66 – Autoimmune peripheral neuropathies , 2008 .

[120]  I. Sanz,et al.  Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. , 2007, Arthritis and rheumatism.

[121]  M. Genovese,et al.  A pilot trial of rituximab in the treatment of patients with dermatomyositis. , 2007, Archives of dermatology.

[122]  M. Duddy,et al.  Distinct Effector Cytokine Profiles of Memory and Naive Human B Cell Subsets and Implication in Multiple Sclerosis , 2007, The Journal of Immunology.

[123]  Steven A Greenberg,et al.  Myeloid dendritic cells in inclusion‐body myositis and polymyositis , 2007, Muscle & nerve.

[124]  L. Erickson,et al.  Imprinting the Fate of Antigen-Reactive B Cells through the Affinity of the B Cell Receptor1 , 2006, The Journal of Immunology.

[125]  Michael J. Ramsbottom,et al.  Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients , 2006, Journal of Neuroimmunology.

[126]  Fang Qian,et al.  Formation of virus-like clusters is an intrinsic property of the tumor necrosis factor family member BAFF (B cell activating factor). , 2006, Biochemistry.

[127]  J. Tschopp,et al.  Identification of proteoglycans as the APRIL-specific binding partners , 2005, The Journal of experimental medicine.

[128]  E. Waubant,et al.  An open label study of the effects of rituximab in neuromyelitis optica , 2005, Neurology.

[129]  P. Fuhr,et al.  IgM deposits on skin nerves in anti–myelin‐associated glycoprotein neuropathy , 2005, Annals of neurology.

[130]  J. Satoh,et al.  Nogo-A and Nogo Receptor Expression in Demyelinating Lesions of Multiple Sclerosis , 2005, Journal of neuropathology and experimental neurology.

[131]  T. Levine.  Rituximab in the treatment of dermatomyositis: an open-label pilot study. , 2005, Arthritis and rheumatism.

[132]  Yen-Ming Hsu,et al.  Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA. , 2005, Biochemistry.

[133]  A. Rosenwald,et al.  BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma , 2005, The Journal of experimental medicine.

[134]  K. Haas,et al.  CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction. , 2005, Advances in immunology.

[135]  A. Uccelli,et al.  Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[136]  K. Tarte,et al.  BAFF and APRIL protect myeloma cells from apoptosis induced by IL-6 deprivation and dexamethasone , 2003 .

[137]  B. Diamond,et al.  B-cell biology. , 2004, Rheumatic diseases clinics of North America.

[138]  R. Bram,et al.  BCMA Is Essential for the Survival of Long-lived Bone Marrow Plasma Cells , 2004, The Journal of experimental medicine.

[139]  H. Willison,et al.  Peripheral neuropathies and anti-glycolipid antibodies. , 2002, Brain : a journal of neurology.

[140]  H. Shu,et al.  Crystal Structure of sTALL-1 Reveals a Virus-like Assembly of TNF Family Ligands , 2002, Cell.

[141]  V. Dixit,et al.  Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency , 2001, Current Biology.

[142]  M. López‐Fraga,et al.  Biologically active APRIL is secreted following intracellular processing in the Golgi apparatus by furin convertase , 2001, EMBO reports.

[143]  D. Jacobowitz,et al.  Stiff person syndrome: Advances in pathogenesis and therapeutic interventions , 2001, Neurology.

[144]  T. Tedder,et al.  CD19 regulates intrinsic B lymphocyte signal transduction and activation through a novel mechanism of processive amplification , 2000, Immunologic research.

[145]  Link,et al.  Increased levels of circulating acetylcholine receptor (AChR)‐reactive IL‐10‐secreting cells are characteristic for myasthenia gravis (MG) , 1999, Clinical and experimental immunology.

[146]  Amy S Orr,et al.  BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. , 1999, Science.

[147]  J. Tschopp,et al.  BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth , 1999, The Journal of experimental medicine.

[148]  J. Tschopp,et al.  APRIL, a New Ligand of the Tumor Necrosis Factor Family, Stimulates Tumor Cell Growth , 1998, The Journal of experimental medicine.

[149]  R. Pirskanen,et al.  Polymorphisms in IL-1β and IL-1 receptor antagonist genes are associated with myasthenia gravis , 1998, Journal of Neuroimmunology.

[150]  R. Pirskanen,et al.  Polymorphisms in IL-1beta and IL-1 receptor antagonist genes are associated with myasthenia gravis. , 1998, Journal of neuroimmunology.

[151]  K. Jellinger,et al.  Patterns of oligodendroglia pathology in multiple sclerosis. , 1994, Brain : a journal of neurology.

[152]  S. Berrih-Aknin,et al.  High IL‐6 Gene Expression and Production by Cultured Human Thymic Epithelial Cells from Patients with Myasthenia Gravis , 1993, Annals of the New York Academy of Sciences.

[153]  J. Sprent,et al.  Synergy between encephalitogenic T cells and myelin basic protein-specific antibodies in the induction of experimental autoimmune encephalomyelitis , 1992, Journal of Neuroimmunology.

[154]  G. Moretto,et al.  Complement-mediated demyelination in patients with IgM monoclonal gammopathy and polyneuropathy. , 1990, The New England journal of medicine.

[155]  J. England,et al.  Guillain-Barr Syndrome , 1990 .

[156]  D. Willenborg,et al.  Immunoglobulin-deficient rats fail to develop experimental allergic encephalomyelitis , 1983, Journal of Neuroimmunology.

[157]  W. Engel,et al.  Immunoglobulin and complement deposits in nerves of patients with chronic relapsing polyneuropathy. , 1980, Archives of neurology.

[158]  W. Engel,et al.  CSF “monoclonal” bands in chronic relapsing polyneuropathy , 1980, Neurology.